Abstract
Solifenacin succinate, a competitive muscarinic receptor antagonist, is one of the newer options for the treatment of overactive bladder in men and women. Objective: To review the pharmacology, efficacy and tolerability for the treatment of overactive bladder with solifenacin succinate. Methods: A literature search was done using the keywords YM905 and solifenacin succinate. Conclusion: Solifenacin succinate was shown to be effective for symptom control with an increase in volume voided, improvement in quality of life and a decrease in a common side effect of dry mouth compared to other medications.